Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Florida (PRWEB) April 23, 2015 ... it intends to conduct a groundbreaking pilot study ... to be reversed in as little as three ... science of metabolic and nutritional medicine—will aggressively target ... cripple and destroy our aging brain. These include ...
(Date:4/23/2015)... ORLANDO, Fla. , April 23, 2015 ... . releases his book "Age Healthier Live Happier - ... kick off the Age Management Medicine Group Conference at ... - 26, 2015. ",Age Healthier Live Happier, ... looking to avoid over-medication and searching for a higher ...
(Date:4/23/2015)... SAN DIEGO , April 23, 2015  Neurocrine ... the Company will report its first quarter 2015 results ... 2015. Neurocrine will then host a live conference call and ... Company update Thursday morning, April 30, 2015 at 8:00 ... Participants can access the live conference call by dialing ...
(Date:4/23/2015)... California (PRWEB) April 23, 2015 ... diagnostics refer to a series of genetic tests ... cystic fibrosis, Lou Gehrig's disease, Huntington's disease, and ... examining the gene composition and interaction in diseased ... disease as well as the response to treatment, ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3
... iAdvantage Software, Inc. , a leading provider ... studies, today announced that Springborn , a ... the eStudy(TM) hosted solution to manage ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090616/CL33492LOGO ) ...
... , - Dosimetry Study Results Show Greater Than 300-Fold More ... , , - All Patients in the First Two Cohorts ... GBM Patients - , , TORONTO and TUSTIN, Calif., June ... reported that researchers will present data at the SNM 2009 Annual ...
... Finance 2009 , , ARVADA, Colo., June 16 ... service and responsibility to our shareholders, is addressing our ... Pharma Finance 2009, a Biotechnology, Medical Devices, and world ... June 4-5. , , Pharma Finance is an ...
Cached Biology Technology:Springborn Deploys eStudy(TM) Hosted Solution for Management of Global Environmental Testing 2Springborn Deploys eStudy(TM) Hosted Solution for Management of Global Environmental Testing 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 2Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 4Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 5Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 6GeneThera Extends its Reach Overseas 2
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... UC Santa Barbara,s Institute for Collaborative Biotechnologies (ICB) ... the U.S. Army Research Laboratory-Army Research Office, providing ... support research that is inspired by biological systems. ... success of a decade of fundamental research in ...
... about how the brain calculates and remembers where it iswhich ... award the 2013 Louisa Gross Horwitz Prize to Edvard I. ... of Science and Technology in Norway, and John Michael O,Keefe, ... conducted in animal models, may lead to new treatments for ...
... world,s oldest ocean predators have long been a genetic mystery. ... code has fished up big surprises behind a design so ... Cornell researchers have discovered that many of the endangered great ... including metabolism match humans more closely than they ...
Cached Biology News:Army renews bio-inspired engineering and science research center at UC Santa Barbara with $48 million 2Army renews bio-inspired engineering and science research center at UC Santa Barbara with $48 million 3Columbia's 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimer's treatments 2Columbia's 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimer's treatments 3Columbia's 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimer's treatments 4Columbia's 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimer's treatments 5New genetic research finds shark, human proteins stunningly similar 2
... cells-directed transfection reagent : jetPEI-RGD ... which allows targeted efficient transfection ... cells. Integrins are adhesion molecules ... adhesion processes. Many integrins, including ...
...
... MacMelt software is used on ... melting profile of any DNA sequence ... in optimizing placement of primers and ... denaturing gradient gel electrophoresis (DGGE), constant ...
Request Info...
Biology Products: